openPR Logo
Press release

Top News: Neuromyelitis Optica Spectrum Disorder Market Advancements 2019 - 2027

05-22-2020 05:14 PM CET | Health & Medicine

Press release from: Transparency Market Research

Top News: Neuromyelitis Optica Spectrum Disorder Market

Neuromyelitis Optica Spectrum Disorder Market: Introduction
Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of central nervous system which was previously known as Devic disease or neuromyelitis optica (NMO). It is a rare debilitating and lifelong disease characterized by inflammation in spinal cord and optic nerve.
View Report : https://www.transparencymarketresearch.com/neuromyelitis-optica-spectrum-disorder-market.html

People with neuromyelitis optica spectrum disorder experience symptoms such as paralysis, muscle weakness, and blindness. Neuromyelitis optica spectrum disorder is most common in non-Caucasian women
Key Drivers and Opportunities of Global Neuromyelitis Optica Spectrum Disorder Market
Rise in incidence of neuromyelitis optica spectrum disorder is likely propel the neuromyelitis optica spectrum disorder market. For instance, according to an article published in Neurology, in Denmark, the incidence of neuromyelitis optica spectrum disorder was 0.070 per 100,000 person-years and the prevalence was 1.09 per 100,000 in 2015.
Moreover, increase in research & development by key players is anticipated to drive the market. Several players are investing in development of products for the treatment of neuromyelitis optica spectrum disorder. Thus, key players have a strong pipeline.
In December 2019, F. Hoffmann-La Roche Ltd announced the pivotal phase III study of the investigational medicine satralizumab for the treatment of neuromyelitis optica spectrum disorder
Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76323

In 2019, inebilizumab (Anti-CD19 mAb) completed phase III clinical trial for neuromyelitis optica spectrum disorder. It is offered by Viela Bio.
Satralizumab offered by Genentech is in phase III clinical trial. It is an investigational humanized monoclonal antibody that targets IL-6 receptor. It is being evaluated for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
Furthermore, introduction of new products by key players is anticipated to drive the neuromyelitis optica spectrum disorder market. For instance, in June 2019, Alexion Pharmaceuticals, Inc. received approval for Soliris injection for the treatment of neuromyelitis optica spectrum disorder in adult patients.
Emergence of new therapies for acute phase or prevention of neuromyelitis optica spectrum disorder creates lucrative opportunity for the market. Emerging therapies for acute phase and prevention are Bevacizumab (anti-VEGF mAb) and Alpha1-antitrypsin; and Eculizumab (anti-C5 mAb) and Rituximab (anti-CD20 mAb), respectively.
REQUEST FOR COVID19 IMPACT ANALYSIS - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=76323

North America to Capture Major Share of Global Neuromyelitis Optica Spectrum Disorder Market
North America is expected to account for major share of the global neuromyelitis optica spectrum disorder market due to new product launch and approval. For instance, in October 2019, the U.S. Food and Drug Administration accepted Genentech's Biologics License Application (BLA) for satralizumab for the treatment of neuromyelitis optica spectrum disorder in adults and adolescents. In December 2018, Chugai's anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab granted the Breakthrough Therapy Designation from U.S. Food and Drug Administration. It is an investigational medicine for the treatment of neuromyelitis optica spectrum disorders and neuromyelitis optica.
The neuromyelitis optica spectrum disorder market in Asia Pacific is expected to grow at a rapid pace during the forecast period, owing to rise in prevalence of NMOSD. For instance, according to a study published in Neurology, in 2016, the prevalence of NMOSD was 4.1 per 100,000 in northern Japan and it was higher in females than males.
Buy Now Report : https://www.transparencymarketresearch.com/checkout.php?rep_id=76323<ype=S

Key Players Operating in Global Neuromyelitis Optica Spectrum Disorder Market
The global neuromyelitis optica spectrum disorder market is highly concentrated due to the presence of key players. A large number of manufacturers hold major share in their respective regions.

Demand for neuromyelitis optica spectrum disorder treatment products has increased in emerging as well as developed markets, thus, the key players are engaged developing new products and investing in research & development. In August 2019, Alexion Pharmaceuticals, Inc. received approval from European Commission for SOLIRIS (Eculizumab) for the treatment of neuromyelitis optica spectrum disorder.

Major players operating in the global neuromyelitis optica spectrum disorder market are:
Alexion Pharmaceuticals, Inc.
Hoffmann-La Roche Ltd
Viela Bio
Genentech, Inc.
AstraZeneca
Global Neuromyelitis Optica Spectrum Disorder Market: Research Scope
Global Neuromyelitis Optica Spectrum Disorder Market, by Therapy
Drug Therapy
Immunomodulators
Azathioprine
Mycophenolate
Rituximab
Methotrexate
Others
Corticosteroids
Others
Plasma Exchange
More Trending Reports by Transparency Market Research - 1. http://www.prnewswire.com/news-releases/animal-health-gains-prominence-as-role-shifts-from-pets-to-companions-contributing-to-growth-in-veterinary-radiography-system-market-notes-tmr-301022155.html

2. https://www.biospace.com/article/fetal-monitoring-systems-market-efm-combined-with-machine-learning-help-extract-new-discriminating-information/

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Top News: Neuromyelitis Optica Spectrum Disorder Market Advancements 2019 - 2027 here

News-ID: 2055431 • Views:

More Releases from Transparency Market Research

Global Solar Powered Agricultural Dryer Market to Exceed USD 2.4 Billion by 2031 - Transparency Market Research
Global Solar Powered Agricultural Dryer Market to Exceed USD 2.4 Billion by 2031 …
The global solar powered agricultural dryer market, valued at US$ 1.6 billion in 2022, is projected to grow at a CAGR of 5.8% from 2023 to 2031, reaching US$ 2.4 billion by the end of 2031. Rising investments in renewable energy, growing awareness of sustainable agricultural practices, and the rapid expansion of the agricultural sector driven by population growth are key factors fueling market growth. Uncover essential discoveries and trends from
Technetium-99m Market Forecast 2034: Rising Demand for Diagnostic Imaging and Radiopharmaceuticals to Propel Market Expansion | Transparency Market Research, Inc
Technetium-99m Market Forecast 2034: Rising Demand for Diagnostic Imaging and Ra …
The global Technetium‐99m Market was valued at US$ 6.0 Billion in 2023 and is projected to grow at a CAGR of 3.3% from 2024 to 2034, surpassing US$ 8.6 Billion by the end of the forecast period. Advancements in nuclear imaging infrastructure, government-backed healthcare initiatives, and an increasing demand for precise diagnostic procedures are fueling this growth. Discover essential conclusions and data from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=77100 Analysts' Viewpoint The Technetium‐99m
Equine Diagnostic Services Market Outlook 2030: From US$ 168 Million in 2019 to US$ 280 Million by 2030, Driven by Rising Equine Diseases and Diagnostic Advancements
Equine Diagnostic Services Market Outlook 2030: From US$ 168 Million in 2019 to …
The global Equine Diagnostic Services Market, valued at approximately US$ 168 million in 2019, is projected to expand at a compound annual growth rate (CAGR) of ~5% from 2020 to 2030, reaching around US$ 280 million by 2030. Equine diagnostic services, encompassing tests like genetic, infectious disease, and imaging diagnostics, are critical for managing horse health in veterinary hospitals, clinics, and mobile settings. The market is driven by increasing equine
Digital Printing Market to Reach USD 54.4 Billion by 2034, Growing at a CAGR of 6.1%
Digital Printing Market to Reach USD 54.4 Billion by 2034, Growing at a CAGR of …
The digital printing market is experiencing strong growth, driven by rapid technological advancements, rising demand for personalized and on-demand printing, and an increasing focus on sustainable solutions. Digital printing allows for the direct transfer of digital files onto a wide range of substrates, offering high-resolution output with greater speed and flexibility. Its adaptability has led to broad adoption across industries such as packaging, textiles, publishing, and advertising-sectors where customization, efficiency,

All 5 Releases


More Releases for Neuromyelitis

Neuromyelitis Optica Spectrum Disorder Market
According to a new market research report published by Global Market Estimates, the Global Neuromyelitis Optica Spectrum Disorder Market is projected to grow at a CAGR of 6.2% from 2023 to 2028. F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi (France), Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Zydus Cadila, Boehringer Ingelheim International GmbH., Apotex Inc., and AstraZeneca among others, are some of the key players in the global
Neuromyelitis Optica Drug Market Therapeutic Survey Reviews, Analysis 2025
The report titled “Neuromyelitis Optica Drug Market” has recently added by MarketInsightsReports to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners, and industry experts. The Neuromyelitis Optica Drug was valued
Drugs for Neuromyelitis Optica Market Size, Share, Development by 2025
LP INFORMATION recently released a research report on the Drugs for Neuromyelitis Optica market analysis, which studies the Drugs for Neuromyelitis Optica's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global "Drugs for Neuromyelitis Optica Market 2020-2025" Research Report categorizes the global Drugs for Neuromyelitis Optica market by key players, product type, applications and regions,etc. The report also covers the latest
Neuromyelitis Optica Therapy Market 2020 Analysis and Research Report 2025
The Neuromyelitis Optica Therapy Market report is a collection of useful information, quantitative and qualitative estimation by industry experts, the contribution from industry connoisseurs and industry accomplices across the value chain. Furthermore, the report also provides the qualitative results of diverse market factors on its geographies and segments. In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and
Global Neuromyelitis Optica Drug Market Research Report 2016
Qyresearchreports include new market research report”Global Neuromyelitis Optica Drug Market Research Report 2016″ to its huge collection of research reports. A new research report on the global Neuromyelitis Optica Drug market offers a 360-degree overview of it. The report discusses the market in significant details and elucidates all aspects of the global Neuromyelitis Optica Drug market likely to impact its growth trajectory in the upcoming years. Major market stimulants and deterrents
Global Neuromyelitis Optica Drug Market- Baxter, CSL, CBOP, TEVA
Global Market Study Evaluate on Neuromyelitis Optica Drug Industry by Type, Manufacturers, Application, Type, and Regions, Forecast up to 2022 Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and